GLP-1s are one of the biggest advances in metabolic health in a generation.
They do what willpower never could, because appetite was never willpower.
For decades, the advice was: eat less, try harder, become a better moral citizen in the supermarket aisle.
For millions, that advice failed.
Then a weekly injection quieted the hunger no amount of motivational nonsense could touch.
That matters. It retires a lot of misplaced shame. Good.
But this is not a warning about GLP-1s.
It is a warning about using the wrong scoreboard.
Weight is crude. Body composition is the truth.
A meaningful share of GLP-1 weight loss can come from lean mass: muscle, bone, and the structure that keeps you functional.
Lose 20% of your body weight without tracking composition and you may be lighter, but weaker.
Congratulations. You downsized the building and accidentally removed some of the load-bearing walls.
The prize is not “less weight”.
The prize is less fat, preserved strength, better glucose control, lower risk, and decades of more capable living.
Two measurements change the game.
First: DEXA before the first dose, then repeated on schedule.
Track fat, lean mass, and bone. Not just the number your bathroom scale coughs up like an oracle with bad training data.
Second: a strength marker.
Grip strength. A tracked lift. Something real. Something that tells you whether the machine still works.
Then come the compounders.
Protein. Daily.
Resistance training. Weekly.
The drug removes the appetite that helped build the body you have. Load is what tells the body what to keep.
Train while you are on it and you are not just losing weight. You are banking strength.
Use the window.
One planning note: these are usually long-term therapies. Stop, and much of the weight often comes back. There is no validated taper that magically solves this.
So use the window.
The next generation makes this even more important. Triple agonists like retatrutide are pushing weight loss beyond 24% in trials. But the lean-mass question does not disappear. More weight lost still means more structure at risk if the basics are ignored.
The population story is still early.
GLP-1s are already a massive market. Usage has surged. But the population-level obesity numbers have barely moved.
That sounds contradictory until you remember the boring part humans keep trying to skip.
The drug works for the person who stays the course and builds strength underneath it.
At scale, most people do not yet do both.
On. Off. Regain. Net little.
Movement is medicine. GLP-1s may be its best new partner.
One clears the path.
The other builds what holds.
The drug can take the weight.
What remains is up to the system you build around it.
